BCR/ABL
BCR: a new target in resistance mediated by BCR/ABL-315I?
... Targeting BCR/ABL with Tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias but the “gatekeeper”mutation T315I confers resistance ...
11
c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia
... a BCR-ABL-dependent regulatory feedback mechanism that posttranslationally stimulates Separase proteolytic activity after IM-induced decreases of Separase expres- sion in b3a2 BCR-ABL fusion ...
9
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
... Dasatinib (BMS-354825) is a peculiar DFG-in inhibi- tor, even though it is not effective in the case of T315I mutation [22]. Compared to imatinib, dasatinib enables patients with chronic phase CML to achieve faster and ...
14
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia
... in BCR-ABL positive cells, likely due to reduced levels of topoisomerase II isoforms, and causes increased cell cycle arrest in these ...to BCR-ABL positive cells by inhibiting the oncogene ...
16
The Effect of Bcr-Abl Protein Tyrosine Kinase on Maturation and Proliferation of Primitive Haematopoietic Cells
... We used five-color multiparameter flow cy- tometry to analyze the most primitive human stem cells identified to date (CD34 Lin- Thy Rh-123lo), which have been functionally defined by their ability to initiate long-term ...
11
Targeting BCR-ABL-Independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition
... develop BCR-ABL-independent mechanisms of resistance, and therefore fail ponatinib treat- ...developed BCR-ABL-independent activation of ...
12
Frequency of Bcr Abl Fusion Oncogene Splice Variants Associated with Chronic Myeloid Leukemia (CML)
... of BCR-ABL fusion oncogene in Pakistani child- hood ALL patients was reported to be 49%, which is higher as compared to other reports from around the world ...
5
Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases
... kinase BCR-ABL fusion protein is the product of the Philadel- phia chromosome, which results from the reciprocal translocation t(9;22)(q34;q11) that juxtaposes the c-abl oncogene 1 on chromosome 9 ...
5
Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice
... 18. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW,Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic ...
6
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
... Janus kinases (JAKs) are a family of intracellular, non- receptor tyrosine kinases including four family mem- bers such as JAK1, JAK2, JAK3, and Tyk2. JAK signaling pathways are required for cytokine and growth factor ...
11
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene
... in BCR-ABL positive CML cell lines and primary CD34-enriched cells from CML ...by BCR- ABL via the PI3K/AKT pathway [19], as a transcriptional repressor of ZNF224 in ...mediates ...
15
The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias
... the Bcr-Abl/NF-κB connection [66] in vitro. Using a Bcr-Abl-BaF3 cell line, a Il-3 dependent murine pro B cell line, it was shown that NF-κB activation is partially dependent by IκB-α ...
12
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR ABL activity
... produces BCR-ABL, a constitutively active tyro- sine kinase that drives expansion of leukemic progeny ...the ABL kinase inhibitor imatinib (Gleevec; Novartis) induces complete cytogenetic responses ...
15
Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide
... and bcr-abl antisense oligodeoxynucleotides and assayed for growth ability in clonogenic assays and in immunodeficient ...mice. Bcr-abl transcripts were not detected in residual colonies, and ...
10
Bcr Abl regulates osteopontin transcription via Ras, PI 3K, aPKC, Raf 1 and MEK
... active Bcr-Abl tyrosine ...in Bcr-Abl ...p210 Bcr-Abl. We have determined that high levels of Bcr-Abl activate a signaling cascade involving the sequential activa- ...
12
Bcr Abl regulates phosphatidylinositol 3 kinase p110gamma transcription and activation is required for proliferation and drug resistance
... p110␥ Activity Is Required for Its Own Expression—To elucidate the downstream affects of increased p110␥ activity in C4 cells, we trans- fected these cells with a dominant negative, kinase-deficient mutant PI3K␥(K832R) ...
10
Leukemogenic Fusion Gene (p190 BCR ABL) Transduction into Hematopoietic Stem/Progenitor Cells in the Common Marmoset
... 2). BCR-ABL was detected in the plasma on day 1 but not day ...contrast, BCR- ABL was detected in peripheral blood MNCs on day 1 and 6 in two ...of BCR-ABL expression after ...
10
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
... their BCR- ABL/BCR ratios showed a reduction to ...of BCR-ABL transcript were measured by RT-qPCR at 4 to 12 weeks beginning in February ...of BCR-ABL were considered ...
8
Frequency of BCR-ABL Fusion Transcripts in Iranian Azeri Turkish patients with Chronic Myeloid Leukemia
... In our study the pattern of BCR-ABL fusion transcripts demonstrated significant differences when compared to others reported from Iran and other geographical areas. Geographical and ethnic differences could ...
5
Therapeutic approaches to enhance the BCR-ABL tyrosine kinase inhibitors efficacy in chronic myeloid leukemia
... into BCR-ABL-dependent and BCR-ABL independent ...mechanisms. BCR-ABL-dependent mechanisms include BCR-ABL mutations and amplification, along with impaired ...
12